NCT07213674 2026-04-16
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
Clinical Trials
14 trialsNCT02044354 2026-04-01
CABA-DOC
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT06691984 2026-03-06
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
Phase 3 Recruiting
NCT06470243 2026-01-22
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
SWOG Cancer Research Network
Phase 3 Recruiting
NCT01952223 2025-07-30
PEACE2
UNICANCER
Phase 3 Active not recruiting
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT02961257 2022-05-12
CABASTY
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Completed
NCT01308567 2019-06-05
FIRSTANA
Sanofi
Phase 3 Completed
NCT01308580 2017-04-17
PROSELICA
Sanofi
Phase 3 Completed
NCT01083615 2016-10-12
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Achieve Life Sciences
Phase 3 Terminated
NCT01578655 2016-10-12
AFFINITY
Achieve Life Sciences
Phase 3 Completed
NCT01978873 2016-05-04
SensiCab
Örebro University, Sweden
Phase 3 Unknown
NCT01254279 2015-01-21
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Sanofi
Phase 3 Completed
NCT00417079 2011-03-10
TROPIC
Sanofi
Phase 3 Completed